ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2026)
ARS Pharmaceuticals (SPRY) posted Assets Average of $307.6 million for Q1 2026, down 12.17% sequentially from $350.2 million in Q4 2025, and down 9.32% YoY from $339.2 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Assets Average for 6 years, with the latest figure at $307.6 million in Q1 2026.
- Quarterly Assets Average fell 9.32% year-over-year to $307.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307.6 million (down 9.32% YoY) and the FY2025 annual result came in at $339.4 million, up 16.17% from the prior year.
- Assets Average slipped to $307.6 million in Q1 2026 per SPRY's latest filing, from $350.2 million in the prior quarter.
- Over five years, Assets Average peaked at $350.2 million in Q4 2025 and troughed at $187.0 million in Q1 2022.
- A 5-year average of $276.7 million and a median of $276.3 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average tumbled 51.88% in 2022, then soared 56.13% in 2025.
- Over 5 years, Assets Average stood at $276.2 million in 2022, then fell by 12.81% to $240.9 million in 2023, then gained by 18.06% to $284.4 million in 2024, then increased by 23.16% to $350.2 million in 2025, then dropped by 12.17% to $307.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $307.6 million, $350.2 million, and $343.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 268.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 268.53 Mn |
| Mar 31, 2026 | 307.61 Mn |
| Dec 31, 2025 | 350.23 Mn |
| Sep 30, 2025 | 343.14 Mn |
| Jun 30, 2025 | 320.40 Mn |
| Mar 31, 2025 | 339.24 Mn |
| Dec 31, 2024 | 284.38 Mn |
| Sep 30, 2024 | 219.78 Mn |
| Jun 30, 2024 | 224.77 Mn |
| Mar 31, 2024 | 230.39 Mn |
| Dec 31, 2023 | 240.87 Mn |
| Sep 30, 2023 | 253.65 Mn |
| Jun 30, 2023 | 264.97 Mn |
| Mar 31, 2023 | 276.31 Mn |
| Dec 31, 2022 | 276.25 Mn |
| Sep 30, 2022 | 282.53 Mn |
| Jun 30, 2022 | 303.23 Mn |
| Mar 31, 2022 | 186.96 Mn |
| Dec 31, 2021 | 207.00 Mn |
| Sep 30, 2021 | 359.77 Mn |